FDA Cleared ≠ FDA Validated - Summary - MDSpire

FDA Cleared ≠ FDA Validated

Most AI medical devices reach the market without independent evidence of safety or effectiveness.

  • By

  • Kerri Miller

  • May 4, 2026

  • 2 min

Share

Objective:

To highlight the discrepancies between FDA clearance of AI medical devices and the actual validation of their safety and effectiveness, emphasizing the misconceptions held by clinicians.

Key Findings:
  • Over 1,400 AI medical devices are on the market, with 97% cleared via the 510(k) pathway requiring only substantial equivalence.
  • Most physicians mistakenly believe that randomized trials are conducted prior to AI device clinical use, which is often not the case.
  • Existing postmarket surveillance systems, like the MAUDE database, capture a very small percentage of adverse events.
  • There is a significant gap in understanding what FDA clearance entails versus actual device performance and validation.
Interpretation:

There is a critical need for clinicians to understand the limitations of FDA clearance and the actual performance of AI medical devices to ensure safe and effective integration into clinical practice.

Limitations:
  • Postmarket surveillance systems are inadequate for capturing AI/ML performance, leading to potential safety risks.
  • Limited industry participation in monitoring programs hampers data collection and understanding of device performance.
  • Proposed policy changes may reduce transparency for AI tools outside the FDA device pathway, complicating oversight.
Conclusion:

Healthcare providers should not consider FDA clearance as sufficient for due diligence and must demand comprehensive validation data for AI tools, ensuring they understand the limitations of clearance.

Original Source(s)

FDA Cleared ≠ FDA Validated

  • by Kerri Miller

  • May 4, 2026

Related Content

Upfront Cost Guidance Limited in US Guidelines

Although most large US-based medical societies in a cross-sectional study explicitly suggested considering economic or resource use–related evidence during guideline development, only 3.8% of individual recommendations included that information in the recommendation statement itself.

Updated COVID Shot Linked to Added Protection

Updated 2025-2026 vaccination was linked to added protection in a CDC-funded analysis that became part of a broader debate over routine vaccine monitoring.

Stockholm3 Detected More Significant Prostate Cancers Than PSA

In a Swedish population-based screening cohort, the blood-based risk model had higher short-term sensitivity for clinically significant prostate cancer than prostate-specific antigen testing, with similar specificity.